VA
PTGX icon

Vident Advisory’s Protagonist Therapeutics PTGX Stock Holding History

Vident Advisory’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,481
Closed -$472K – 2016
2026
Q1 		$472K Buy
4,481
+290
+7% +$25.7K ﹤0.01% 1288
2025
Q4 		$366K Sell
4,191
-879
-17% -$71.9K ﹤0.01% 1303
2025
Q3 		$337K Buy
+5,070
New +$288K ﹤0.01% 1355

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vident Advisory's PTGX Position: Q2 2026 in Review

Vident Advisory sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 4,481 shares — an estimated $472K sold.

Vident Advisory first reported a position in PTGX in Q3 2025 and held it in 3 quarters. The position peaked at $472K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Vident Advisory reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vident Advisory sold 4,481 Protagonist Therapeutics shares in Q2 2026, an estimated $472K.
  • Vident Advisory first reported a position in Protagonist Therapeutics in Q3 2025 and held it in 3 quarters.
  • Vident Advisory's Protagonist Therapeutics position peaked at $472K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.